Therapy Areas: Oncology
Immunovia announces continued commercialisation of IMMray PanCan-d test in the US
5 December 2022 -

Diagnostics company Immunovia (Nasdaq Stockholm: IMMNOV) reported on Monday that it is continuing to commercialise its IMMray PanCan-d test in the US with the appointment of a new national sales director by its US subsidiary, Immunovia Inc.

The company's IMMray PanCan-d test is the world's first blood test dedicated to the early detection of pancreatic cancer.

Commercialization of IMMray PanCan-d started in August 2021 in the US. The test is offered as a laboratory developed test (LDT) exclusively through Immunovia Inc.

Immunovia added that Jon Hager starts in his position of national sales director on 5 December 2022.

Hager worked at Myriad Genetics where he was a core member of the team that launched hereditary cancer testing to gynecologists.



Related Headlines